Last reviewed · How we verify
PTT-4256
At a glance
| Generic name | PTT-4256 |
|---|---|
| Sponsor | Pathios Therapeutics Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTT-4256 CI brief — competitive landscape report
- PTT-4256 updates RSS · CI watch RSS
- Pathios Therapeutics Pty Ltd portfolio CI